YAP1 and hepatocellular carcinoma: Our results indicated that the combination treatment significantly inhibited the YAP target gene expression in HCC cell lines but had little effect on cells expressing YAP1S127A (Fig. S9E), suggesting that combination treatment with Roblitinib and CPI-169 repressed the oncogenic gene expression programs, including the anti-apoptotic gene expression programs, in a YAP signaling-dependent manner.